PMID- 18182069
OWN - NLM
STAT- MEDLINE
DCOM- 20081208
LR  - 20220408
IS  - 1601-183X (Electronic)
IS  - 1601-183X (Linking)
VI  - 7
IP  - 5
DP  - 2008 Jul
TI  - BDNF variability in opioid addicts and response to methadone treatment: 
      preliminary findings.
PG  - 515-22
LID - 10.1111/j.1601-183X.2007.00386.x [doi]
AB  - Brain-derived neurotrophic factor (BDNF) signaling pathways have been shown to be 
      essential for opioid-induced plasticity. We conducted an exploratory study to 
      evaluate BDNF variability in opioid addict responders and nonresponders to 
      methadone maintenance treatment (MMT). We analyzed 21 single nucleotide 
      polymorphisms (SNPs) across the BDNF genomic region. Responders and nonresponders 
      were classified by means of illicit opioid consumption detected in random 
      urinalysis. Patients were assessed by a structured interview (Psychiatric 
      Research Interview for Substance and Mental Disorders (PRISM)-DSM-IV) and 
      personality was evaluated by the Cloninger's Temperament and Character Inventory. 
      No clinical, environmental and treatment characteristics were different between 
      the groups, except for the Cooperativeness dimension (P < 0.001). Haplotype block 
      analysis showed a low-frequency (2.7%) haplotype (13 SNPs) in block 1, which was 
      more frequent in the nonresponder group than in the responder group (4/42 vs. 
      1/135; P(corrected) = 0.023). Fine mapping in block 1 allows us to identify a 
      haplotype subset formed by only six SNPs (rs7127507, rs1967554, rs11030118, 
      rs988748, rs2030324 and rs11030119) associated with differential response to MMT 
      (global P sim = 0.011). Carriers of the CCGCCG haplotype had an increased risk of 
      poorer response, even after adjusting for Cooperativeness score (OR = 20.25 95% 
      CI 1.46-280.50, P = 0.025). These preliminary results might suggest the 
      involvement of BDNF as a factor to be taken into account in the response to MMT 
      independently of personality traits, environmental cues, methadone dosage and 
      psychiatric comorbidity.
FAU - de Cid, R
AU  - de Cid R
AD  - Genes and Disease Program, Center for Genomic Regulation (CRG) and CIBER 
      Epidemiologia y Salud Publica (CIBERESP), Barcelona, Spain.
FAU - Fonseca, F
AU  - Fonseca F
FAU - Gratacos, M
AU  - Gratacos M
FAU - Gutierrez, F
AU  - Gutierrez F
FAU - Martin-Santos, R
AU  - Martin-Santos R
FAU - Estivill, X
AU  - Estivill X
FAU - Torrens, M
AU  - Torrens M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Genes Brain Behav
JT  - Genes, brain, and behavior
JID - 101129617
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - UC6VBE7V1Z (Methadone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Analgesics, Opioid/*therapeutic use
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Cohort Studies
MH  - Comorbidity
MH  - Drug Resistance/genetics
MH  - Female
MH  - Genetic Variation
MH  - Haplotypes
MH  - Humans
MH  - Male
MH  - Methadone/*therapeutic use
MH  - Middle Aged
MH  - Opioid-Related Disorders/*drug therapy/epidemiology/*genetics
MH  - Personality/genetics
MH  - Pharmacogenetics
MH  - Polymorphism, Single Nucleotide
EDAT- 2008/01/10 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/01/10 09:00
PHST- 2008/01/10 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/01/10 09:00 [entrez]
AID - GBB386 [pii]
AID - 10.1111/j.1601-183X.2007.00386.x [doi]
PST - ppublish
SO  - Genes Brain Behav. 2008 Jul;7(5):515-22. doi: 10.1111/j.1601-183X.2007.00386.x.